186 related articles for article (PubMed ID: 23571426)
1. Immunoglobulin Fc domain fusion to apolipoprotein(a) kringle V significantly prolongs plasma half-life without affecting its anti-angiogenic activity.
Yu HK; Lee HJ; Ahn JH; Lim IH; Moon JH; Yoon Y; Yi LS; Kim SJ; Kim JS
Protein Eng Des Sel; 2013 Jun; 26(6):425-32. PubMed ID: 23571426
[TBL] [Abstract][Full Text] [Related]
2. Repeated intravenous infusion of human apolipoprotein(a) kringle V is associated with reversible dose-dependent acute tubulointerstitial nephritis without affecting glomerular filtration function.
Lee HJ; Yu HK; Ahn JH; Park YK; Yoon Y; Kim JS; Kim SJ
Toxicol Lett; 2012 Aug; 212(3):298-306. PubMed ID: 22659101
[TBL] [Abstract][Full Text] [Related]
3. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
4. Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model.
Lee HJ; Yu HK; Papadopoulos JN; Kim SW; He J; Park YK; Yoon Y; Kim JS; Kim SJ
Neoplasia; 2012 Apr; 14(4):335-43. PubMed ID: 22577348
[TBL] [Abstract][Full Text] [Related]
5. A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity.
Liu L; Yu H; Huang X; Tan H; Li S; Luo Y; Zhang L; Jiang S; Jia H; Xiong Y; Zhang R; Huang Y; Chu CC; Tian W
BMC Cancer; 2015 Mar; 15():170. PubMed ID: 25881012
[TBL] [Abstract][Full Text] [Related]
6. Secreted human apolipoprotein(a) kringle IV-10 and kringle V inhibit angiogenesis and xenografted tumor growth.
Shen L; Zhu X; Wang Y; Zeng W; Wu G; Xue H; Chen B
Biol Chem; 2008 Feb; 389(2):135-41. PubMed ID: 18163888
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a).
Kim JS; Chang JH; Yu HK; Ahn JH; Yum JS; Lee SK; Jung KH; Park DH; Yoon Y; Byun SM; Chung SI
J Biol Chem; 2003 Aug; 278(31):29000-8. PubMed ID: 12746434
[TBL] [Abstract][Full Text] [Related]
8. [Expression of rhEPO-L-Fc fusion protein and analysis of its bioactivity and pharmacokinetics].
Zhu Q; Huang Z; Huang Y; Qin Y
Sheng Wu Gong Cheng Xue Bao; 2008 Nov; 24(11):1874-9. PubMed ID: 19256332
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
[TBL] [Abstract][Full Text] [Related]
10. Extension of the in vivo half-life of endostatin and its improved anti-tumor activities upon fusion to a humanized antibody against tumor-associated glycoprotein 72 in a mouse model of human colorectal carcinoma.
Lee SH; Jeung IC; Park TW; Lee K; Lee DG; Cho YL; Lee TS; Na HJ; Park YJ; Lee HG; Jeong MS; Bae KH; Lee SC; Lee HJ; Kwon YG; Hong HJ; Kim JS; Min JK
Oncotarget; 2015 Mar; 6(9):7182-94. PubMed ID: 25762629
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice.
Unverdorben F; Richter F; Hutt M; Seifert O; Malinge P; Fischer N; Kontermann RE
MAbs; 2016; 8(1):120-8. PubMed ID: 26514880
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic action of plasma hyaluronan binding protein in human umbilical vein endothelial cells.
Jeon JW; Song HS; Moon EJ; Park SY; Son MJ; Jung SY; Kim JT; Nam DH; Choi-Miura NH; Kim KW; Kim YJ
Int J Oncol; 2006 Jul; 29(1):209-15. PubMed ID: 16773202
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis.
Kim YJ; Bae J; Shin TH; Kang SH; Jeong M; Han Y; Park JH; Kim SK; Kim YS
J Control Release; 2015 Oct; 216():56-68. PubMed ID: 26260451
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human lactoferrin-Fc fusion with an improved plasma half-life.
Shiga Y; Oshima Y; Kojima Y; Sugimoto A; Tamaki N; Murata D; Takeuchi T; Sato A
Eur J Pharm Sci; 2015 Jan; 67():136-143. PubMed ID: 25433245
[TBL] [Abstract][Full Text] [Related]
15. The N-terminal alanine-extended GLP-1/IgG-Fc fusion protein confers resistance to DPP-IV and reduces serum glucose level in db/db mice.
Chung HS; Oh JY; Yoo SB; Lee SM; Cho HS
Regul Pept; 2011 Oct; 170(1-3):1-3. PubMed ID: 21621561
[TBL] [Abstract][Full Text] [Related]
16. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
17. Anti-Tumor Activity and Pharmacokinetics of AP25-Fc Fusion Protein.
Pei D; Hu J; Rao C; Yu P; Xu H; Wang J
Int J Med Sci; 2019; 16(7):1032-1041. PubMed ID: 31341417
[TBL] [Abstract][Full Text] [Related]
18. [Expression of human IL-35-IgG4 (Fc) fusion protein in CHO/DG44 cells].
Tang J; Gao W; Zhang Q; Zhang D; Chen Y; He B; Liu Q
Sheng Wu Gong Cheng Xue Bao; 2009 Jan; 25(1):109-15. PubMed ID: 19441235
[TBL] [Abstract][Full Text] [Related]
19. Suppression of colorectal cancer liver metastasis by apolipoprotein(a) kringle V in a nude mouse model through the induction of apoptosis in tumor-associated endothelial cells.
Ahn JH; Yu HK; Lee HJ; Hong SW; Kim SJ; Kim JS
PLoS One; 2014; 9(4):e93794. PubMed ID: 24699568
[TBL] [Abstract][Full Text] [Related]
20. Atrial natriuretic peptide-Fc, ANP-Fc, fusion proteins: semisynthesis, in vitro activity and pharmacokinetics in rats.
Mezo AR; McDonnell KA; Low SC; Song J; Reidy TJ; Lu Q; Amari JV; Hoehn T; Peters RT; Dumont J; Bitonti AJ
Bioconjug Chem; 2012 Mar; 23(3):518-26. PubMed ID: 22263969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
